Ascletis reaps record $400M from Hong Kong investors in the exchange's first-ever pre-revenue biotech listing
The first pre-revenue biotech to list on Hong Kong’s stock exchange has landed. And its success will likely spur plenty of more such offerings in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
